A novel germline PALB2 deletion in Polish breast and ovarian cancer patients - PubMed (original) (raw)

Comparative Study

A novel germline PALB2 deletion in Polish breast and ovarian cancer patients

Agnieszka Dansonka-Mieszkowska et al. BMC Med Genet. 2010.

Abstract

Background: PALB2 protein was recently identified as a partner of BRCA1 and BRCA2 which determines their proper function in DNA repair.

Methods: Initially, the entire coding sequence of the PALB2 gene with exon/intron boundaries was evaluated by the PCR-SSCP and direct sequencing methods on 70 ovarian carcinomas. Sequence variants of interest were further studied on enlarged groups of ovarian carcinomas (total 339 non-consecutive ovarian carcinomas), blood samples from 334 consecutive sporadic and 648 consecutive familial breast cancer patients, and 1310 healthy controls from central Poland.

Results: Ten types of sequence variants were detected, and among them four novel polymorphisms: c.2996+58T>C in intron 9; c.505C>A (p.L169I), c.618T>G (p.L206L), both in exon 4; and c.2135C>T (A712V) in exon 5 of the PALB2 gene. Another two polymorphisms, c.212-58A>C and c.2014G>C (E672Q) were always detected together, both in cancer (7.5% of patients) and control samples (4.9% of controls, p = 0.2). A novel germline truncating mutation, c.509_510delGA (p.R170fs) was found in exon 4: in 2 of 339 (0.6%) unrelated ovarian cancer patients, in 4 of 648 (0.6%) unrelated familial breast cancer patients, and in 1 of 1310 controls (0.08%, p = 0.1, p = 0.044, respectively). One ovarian cancer patient with the PALB2 mutation had also a germline nonsense mutation of the BRCA2 gene.

Conclusions: The c.509_510delGA is a novel PALB2 mutation that increases the risk of familial breast cancer. Occurrence of the same PALB2 alteration in seven unrelated women suggests that c.509_510delGA (p.R170fs) is a recurrent mutation for Polish population.

PubMed Disclaimer

Figures

Figure 1

Figure 1

The c.509_510delGA detected in the PALB2 gene in ovarian carcinomas. SSCP gel (in the middle) - shifted bands are indicated by arrows; on sequencing diagrams the deletion site is indicated by arrows.

Figure 2

Figure 2

Pedigrees of breast cancer families with PALB2 mutations. Probands with confirmed mutation are indicated by an arrow. Br -breast cancer, Sto -stomach cancer, Liv -liver cancer, Lu - lung cancer, Pan - pancreatic cancer.

Similar articles

Cited by

References

    1. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, Liu X, Jasin M, Couch FJ, Livingston DM. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell. 2006;22:719–729. doi: 10.1016/j.molcel.2006.05.022. - DOI - PubMed
    1. Zhang F, Ma J, Wu J, Ye L, Cai H, Xia B, Yu X. PALB2 Links BRCA1 and BRCA2 in the DNA-Damage Response. Curr Biol. 2009;19:524–529. doi: 10.1016/j.cub.2009.02.018. - DOI - PMC - PubMed
    1. Jacquemont C, Taniguchi T. The Fanconi anemia pathway and ubiquitin. BMC Biochem. 2007;8(Suppl 1):S10. doi: 10.1186/1471-2091-8-S1-S10. - DOI - PMC - PubMed
    1. Taniguchi T, D'Andrea AD. Molecular pathogenesis of Fanconi anemia: recent progress. Blood. 2006;107:4223–4233. doi: 10.1182/blood-2005-10-4240. - DOI - PubMed
    1. Xia B, Dorsman JC, Ameziane N, de Vries Y, Rooimans MA, Sheng Q, Pals G, Errami A, Gluckman E, Llera J. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet. 2007;39:159–161. doi: 10.1038/ng1942. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources